 Crinetics Pharmaceuticals NASDAQ: CRNX recently received a number of ratings updates from brokerages and research firms: 4282020 Crinetics Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, Crinetics Pharmaceuticals Inc is a clinical stage pharmaceutical company. It focuses on the discovery, development and ... 